MX389759B - ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI). - Google Patents

ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).

Info

Publication number
MX389759B
MX389759B MX2019009122A MX2019009122A MX389759B MX 389759 B MX389759 B MX 389759B MX 2019009122 A MX2019009122 A MX 2019009122A MX 2019009122 A MX2019009122 A MX 2019009122A MX 389759 B MX389759 B MX 389759B
Authority
MX
Mexico
Prior art keywords
imperfecta
ostoegenesis
tgfß
antibodies
fragments
Prior art date
Application number
MX2019009122A
Other languages
English (en)
Other versions
MX2019009122A (es
Inventor
Brendan Lee
Kuber T Sampath
Original Assignee
Baylor College Medicine
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50483613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX389759(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baylor College Medicine, Genzyme Corp filed Critical Baylor College Medicine
Publication of MX2019009122A publication Critical patent/MX2019009122A/es
Publication of MX389759B publication Critical patent/MX389759B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar y mejorar los síntomas de la osteogénesis imperfecta (OI) en un sujeto administrando al sujeto una cantidad terapéuticamente eficaz de un agente de unión que se une a factor de crecimiento transformante beta (TGFß).
MX2019009122A 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI). MX389759B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361803647P 2013-03-20 2013-03-20
US201361875399P 2013-09-09 2013-09-09
US201361883151P 2013-09-26 2013-09-26
PCT/US2014/031279 WO2014153435A1 (en) 2013-03-20 2014-03-20 Methods for treating osteogenesis imperfecta

Publications (2)

Publication Number Publication Date
MX2019009122A MX2019009122A (es) 2019-09-16
MX389759B true MX389759B (es) 2025-03-20

Family

ID=50483613

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009122A MX389759B (es) 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).
MX2015013402A MX369360B (es) 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015013402A MX369360B (es) 2013-03-20 2014-03-20 ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I).

Country Status (26)

Country Link
US (4) US9598486B2 (es)
EP (3) EP2976359B2 (es)
JP (3) JP6483086B2 (es)
KR (1) KR102257138B1 (es)
CN (2) CN111000997A (es)
AU (1) AU2014235933B2 (es)
CA (1) CA2907422C (es)
CL (1) CL2015002801A1 (es)
DK (2) DK2976359T4 (es)
EA (1) EA032327B1 (es)
ES (2) ES2763869T3 (es)
HR (2) HRP20181939T4 (es)
HU (1) HUE046702T2 (es)
IL (2) IL241461B (es)
LT (2) LT3312195T (es)
MX (2) MX389759B (es)
MY (1) MY172324A (es)
PH (2) PH12015501864B1 (es)
PL (2) PL2976359T5 (es)
PT (2) PT2976359T (es)
RS (2) RS59673B1 (es)
SG (2) SG10201701985YA (es)
SI (2) SI2976359T2 (es)
TW (1) TWI629995B (es)
UY (1) UY35493A (es)
WO (1) WO2014153435A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032327B1 (ru) * 2013-03-20 2019-05-31 Джензим Корпорейшн Способы лечения несовершенного остеогенеза
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
EP3496755A4 (en) * 2016-08-11 2020-03-11 Precithera, Inc. CONJUGATES OF TGF- ANTAGONISTS.
CN106755395B (zh) * 2016-12-16 2020-05-12 山东第一医科大学(山东省医学科学院) Xi型成骨不全致病基因fkbp10的突变位点及其应用
EA201991729A1 (ru) * 2017-01-20 2019-12-30 Санофи Антитела к tgf-бета и их применение
AR110755A1 (es) * 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
AR110904A1 (es) * 2017-01-20 2019-05-15 Sanofi Sa ANTICUERPOS ANTI-TGF-b Y SU USO
TW202506185A (zh) * 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
CN112703038B (zh) 2018-07-10 2025-07-29 赛诺菲 靶向CD38和TGF-β的抗癌组合疗法
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN110916855A (zh) * 2018-09-20 2020-03-27 天津正天医疗器械有限公司 一种仿生多孔椎间植入物及其制造方法
EP4232063A4 (en) * 2020-10-23 2025-01-01 HAN, Hq BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR-ALPHA AND TRANSFORMING GROWTH FACTOR-BETA AND THEIR USES
BR112023022742A2 (pt) * 2021-05-07 2024-01-02 Baylor College Medicine Tratamento da osteogênese imperfeita moderada a grave
CN113501879B (zh) * 2021-06-30 2022-09-06 拜盖特生物科技(上海)有限公司 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
KR20240111824A (ko) * 2021-11-01 2024-07-17 젠자임 코포레이션 골형성 부전증의 치료
AU2024207355A1 (en) * 2023-01-13 2025-08-21 Chimagen Biosciences, Ltd Multi-specific polypeptide complexes
CN120290673A (zh) * 2025-04-02 2025-07-11 湖北省农业科学院农产品加工与核农技术研究所 一种抗光老化胶原多肽的制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6716836A (es) * 1967-12-11 1969-06-13
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
DE69942782D1 (de) * 1998-11-27 2010-10-28 Ucb Sa Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CA2308532C (en) * 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
EP3520815B1 (en) * 2005-02-08 2021-11-17 Genzyme Corporation Antibodies to tgfbeta
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2007076391A1 (en) 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
WO2008022182A1 (en) * 2006-08-16 2008-02-21 The Uab Research Foundation Methods for promoting coupling between bone formation and resorption
KR101672156B1 (ko) * 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
JP2010528586A (ja) * 2007-04-26 2010-08-26 プレジデント アンド フェローズ オブ ハーバード カレッジ 骨形成及び鉱化作用を調節する化合物の同定のためのアッセイ
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CN101932603A (zh) * 2008-01-15 2010-12-29 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗骨质流失病症的方法
ES2702049T3 (es) * 2009-04-24 2019-02-27 Univ Vanderbilt Inducción anti-TGF-beta de crecimiento óseo
EA032327B1 (ru) * 2013-03-20 2019-05-31 Джензим Корпорейшн Способы лечения несовершенного остеогенеза

Also Published As

Publication number Publication date
EP3640260A1 (en) 2020-04-22
HUE046702T2 (hu) 2020-03-30
RS58188B2 (sr) 2022-06-30
AU2014235933A1 (en) 2015-10-01
PH12019500261A1 (en) 2020-07-20
JP2019089826A (ja) 2019-06-13
PH12015501864A1 (en) 2015-12-07
PL3312195T3 (pl) 2020-04-30
SG10201701985YA (en) 2017-04-27
LT3312195T (lt) 2020-01-10
PT2976359T (pt) 2018-12-05
EA201591843A1 (ru) 2016-01-29
JP7016113B2 (ja) 2022-02-04
MX2019009122A (es) 2019-09-16
EP3312195A1 (en) 2018-04-25
US20160031979A1 (en) 2016-02-04
CN105229028B (zh) 2019-11-08
US12365725B2 (en) 2025-07-22
NZ712353A (en) 2021-04-30
US20190389943A1 (en) 2019-12-26
HRP20181939T1 (hr) 2019-01-25
DK2976359T3 (da) 2019-01-02
HK1213576A1 (en) 2016-07-08
MY172324A (en) 2019-11-21
TWI629995B (zh) 2018-07-21
KR102257138B1 (ko) 2021-05-26
CN105229028A (zh) 2016-01-06
JP6483086B2 (ja) 2019-03-13
CA2907422A1 (en) 2014-09-25
JP2020109110A (ja) 2020-07-16
BR112015023905A2 (pt) 2017-10-24
LT2976359T (lt) 2018-12-27
HK1253717A1 (en) 2019-06-28
DK2976359T4 (da) 2022-06-13
ES2763869T3 (es) 2020-06-01
US10377819B2 (en) 2019-08-13
US11230595B2 (en) 2022-01-25
PL2976359T5 (pl) 2022-07-18
RS59673B1 (sr) 2020-01-31
HRP20192277T1 (hr) 2020-03-06
US9598486B2 (en) 2017-03-21
SG11201506683XA (en) 2015-09-29
EP2976359A1 (en) 2016-01-27
PH12019500261B1 (en) 2021-03-26
CN111000997A (zh) 2020-04-14
PH12015501864B1 (en) 2015-12-07
SI3312195T1 (sl) 2020-02-28
UY35493A (es) 2014-11-28
HRP20181939T4 (hr) 2022-05-13
TW201524515A (zh) 2015-07-01
EP2976359B1 (en) 2018-08-29
WO2014153435A1 (en) 2014-09-25
IL241461A0 (en) 2015-11-30
SI2976359T2 (sl) 2022-05-31
MX2015013402A (es) 2016-01-08
RS58188B1 (sr) 2019-03-29
AU2014235933B2 (en) 2019-01-24
EP2976359B2 (en) 2022-03-23
SI2976359T1 (sl) 2019-03-29
US20170247439A1 (en) 2017-08-31
EA032327B1 (ru) 2019-05-31
ES2700238T5 (es) 2022-05-20
JP2016519093A (ja) 2016-06-30
IL241461B (en) 2021-12-01
PT3312195T (pt) 2019-12-23
MX369360B (es) 2019-11-06
IL287915A (en) 2022-01-01
JP6677837B2 (ja) 2020-04-08
PL2976359T3 (pl) 2019-03-29
KR20150132262A (ko) 2015-11-25
CL2015002801A1 (es) 2016-08-12
US20220195025A1 (en) 2022-06-23
CA2907422C (en) 2021-08-31
ES2700238T3 (es) 2019-02-14
DK3312195T3 (da) 2020-01-06
EP3312195B1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
MX389759B (es) ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTOEGENESIS IMPERFECTA (OI).
MX2016005050A (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenarativos.
CO2018000809A2 (es) Anticuerpos para cd40
PH12015502075B1 (en) Treatment of cataplexy
AR101740A1 (es) Terapia de combinación y composiciones
MX2015011670A (es) Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
EA201690728A1 (ru) Применение молекул, связывающих семафорин-4d, для лечения атеросклероза
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
EA201591786A1 (ru) Монотерапия gla для применения в лечении рака
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX366046B (es) Moléculas de unión que se adhieren al factor de complemento c2 humano y usos de los mismos.
MX385854B (es) Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
EA201791365A1 (ru) Замещенный пиридил-циклоалкил-карбоновые кислоты, содержащие их композиции и их медицинское применение
BR112015023463A2 (pt) uso de sedoeptulose para prevenção ou tratamento de inflamação
CL2016000951A1 (es) Forma cristalina anhidra h de cabazitaxel; proceso de preparación; composición farmacéutica que la comprende; útil para tratar cáncer.
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma